多灶性原发性皮肤间变性大细胞淋巴瘤的治疗结果评估:荷兰皮肤淋巴瘤组报告
荷兰皮肤淋巴瘤组多中心研究评估多灶性原发性皮肤间变性大细胞淋巴瘤(C-ALCL)常规治疗疗效,初诊24例、复发17例(23次复发)。放疗、系统化疗和低剂量甲氨蝶呤的完全缓解率分别为100%、78%和43%;皮损超过5处者皮外复发和死于淋巴瘤的风险更高。
要点
- 皮损≤5处者应接受低剂量放疗(2×4 Gy)。
- 皮损>5处者低剂量甲氨蝶呤(每周20 mg)维持是合适选择。
- 对甲氨蝶呤难治或出现皮外病变的罕见患者可考虑靶向治疗。
核心结论
- 皮损≤5处的多灶性C-ALCL患者应接受低剂量放疗(2×4 Gy)。
- 皮损>5处者低剂量甲氨蝶呤(每周20 mg)维持是合适选择。
- 对甲氨蝶呤难治或出现皮外病变的罕见患者可考虑靶向治疗。
研究设计与样本
- 多中心研究,评估初诊多灶性C-ALCL患者(n=24)或复发多灶性C-ALCL患者(n=17;23次复发)的治疗。
- 区分皮损≤5处患者(n=36)与皮损>5处患者(n=11)。
主要发现
- 最常用治疗为放疗(n=21)、系统化疗(n=9)和低剂量甲氨蝶呤(n=7),完全缓解率分别为100%、78%和43%,总缓解率分别为100%、100%和57%。
- 4例患者出现完全自发消退。
- 初诊多灶性C-ALCL患者24例中16例(67%)复发,包括初始接受CHOP(环磷酰胺、多柔比星、长春新碱和泼尼松)治疗的全部5例患者。
- 与初诊时皮损2至5处的患者相比,初诊时皮损>5处的患者发生皮外复发的机会更高(56% vs. 20%),且更常死于淋巴瘤(44% vs. 7%)。
关键数值与推荐
- 放疗完全缓解率100%、总缓解率100%。
- 系统化疗完全缓解率78%、总缓解率100%。
- 低剂量甲氨蝶呤完全缓解率43%、总缓解率57%。
- 低剂量放疗方案为2×4 Gy。
- 低剂量甲氨蝶呤维持方案为每周20 mg。
临床怎么用
- 皮损≤5处的患者应接受低剂量放疗(2×4 Gy)。
- 皮损>5处的患者低剂量甲氨蝶呤(每周20 mg)维持是合适选择。
- 对甲氨蝶呤难治或出现皮外病变的罕见患者可考虑靶向治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no consensus on the treatment of multifocal primary cutaneous anaplastic large cell lymphoma (C-ALCL). Radiotherapy (RT) and methotrexate (MTX) are the current treatment options, but their efficacy is unknown. Recently, targeted therapies showed promising results in C-ALCL, and may therefore be an attractive first choice of treatment. OBJECTIVES: To assess the efficacy of conventional treatment strategies for patients with multifocal C-ALCL, and to define which patients may require novel targeted therapies. METHODS: In this multicentre study, treatment was evaluated in patients initially presenting (n = 24) or relapsing with multifocal C-ALCL (n = 17; 23 relapses). Distinction was made between patients with five or less lesions (n = 36) and more than five lesions (n = 11). RESULTS: Treatments most commonly used were RT (n = 21), systemic chemotherapy (n = 9) and low-dose MTX (n = 7) with complete response rates of 100%, 78% and 43%, respectively, and an overall response rate of 100%, 100% and 57%, respectively. Four patients showed complete spontaneous regression. In total, 16 of 24 patients (67%) first presenting with multifocal C-ALCL relapsed, including all five patients initially treated with CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone). Compared with patients presenting with two to five skin lesions, patients presenting with more than five lesions had a higher chance of developing extracutaneous relapse (56% vs. 20%) and more often died of lymphoma (44% vs. 7%). CONCLUSIONS: Patients with five or less lesions should be treated with low-dose RT (2 × 4 Gy). Maintenance low-dose MTX (20 mg weekly) is a suitable option in patients with more than five lesions. Targeted therapies may be considered in rare patients who are refractory to MTX or patients developing extracutaneous disease.
引用
- Melchers RC, Willemze R, Bekkenk MW, et al. Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2018. PMID: 29494757. doi:10.1111/bjd.16501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。